| Synonyms: | |
| Status: | Phase 3 |
| Entry Type: | Antibody |
| UNII: | H1396W7D1H |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| INHIBITOR | Lymphocyte activation gene 3 protein inhibitor |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Hodgkin Disease | 3 | D006689 | ClinicalTrials |
| Colorectal Neoplasms | 3 | D015179 | ClinicalTrials |
| Urinary Bladder Neoplasms | 2 | D001749 | ClinicalTrials |
| Urinary Bladder Neoplasms | 2 | D001749 | ClinicalTrials |
| Carcinoma, Non-Small-Cell Lung | 2 | D002289 | ClinicalTrials |
| Small Cell Lung Carcinoma | 1 | D055752 | ClinicalTrials |
| Melanoma | 1 | D008545 | ClinicalTrials |
| Esophageal Neoplasms | 1 | D004938 | ClinicalTrials |
| Lymphoma | 1 | D008223 | ClinicalTrials |
| Neoplasm Metastasis | 1 | D009362 | ClinicalTrials |
| Lymphoma, Non-Hodgkin | 1 | D008228 | ClinicalTrials |
| Carcinoma, Renal Cell | 1 | D002292 | ClinicalTrials |
Cross References
| Resources | Reference |
|---|---|
| ChEMBL | CHEMBL4297784 |
| FDA SRS | H1396W7D1H |
CONTENTS